Beata Diomsina1, Pernille Darling Rasmussen2
1Vilnius University Medical Faculty Psychaitric Clinic, Vilnius, Lithuania
2Child and Adolescent Psychiatric Clinic in Holbaek, Region Zealand, Denmark
Objective: The aim of this study is to share clinical experience with Aripiprazol (Abilify) in treatment of children and adolescents.
Method: The sample (n=33) consists of children and adolescent patients (age 9-18) in treatment with Aripiprazol at the Child and Adolescent Psychiatric Clinic 1 (Roskilde, Denmark) in June 2013. All diagnoses were included and covered severe conduct problems (high impulsivity, aggression, outward reaction, and physical cross-border behavior), high restlessness with ADHD, psychotic and psychosis-like symptoms with autistic disorders, psychosis, and intensive tics with Tourette’s syndrome. The study was conducted as a Cross-sectional study with detailed description of all patients included.
Results: Indications for the treatment and effectiveness of Aripiprazol, Aripiprazol’s common doses used in children and adolescents, and the most commonly observed adverse effects of Abilify are presented. Statistical analysis found that in cases of complex diagnoses, dosage does not depend on age but on other factors. Statistical analysis furthermore found that the effect of treatment is better for those who did experience weight gain.
Conclusions: The findings suggest Aripiprazol to be effective, well tolerated and safe for children and adolescents. Furthermore the dose depends on the complexity of diagnosis (higher doses used in cases of complex diagnosis), on the age (higher doses used in older children, but only in the case of noncomplex diagnoses). Larger studies preferably with RCT design is needed to confirm these findings.